16 Aug

Immunogenicity risk in Multiple Sclerosis, paper in JCI Insight

In a recent paper, published in Journal of Clinical Investigation Insight, we describe a number of factors that influence the risk of immunogenicity responses (anti drug antibodies, ADA) in Multiple Sclerosis patients treated with Interferon beta (IFN-β). We found that NOTCH2 expression on CD14+ cells and increased frequency of proinflammatory monocyte subsets can be used as baseline predictors of neutralizing ADA  (nADA) in MS patients treated with IFN-β. Further investigation of NOTCH2 showed that nADA development was driven by a proinflammatory environment that triggered activation of the NOTCH2 signaling pathway prior to first IFN-β administration.

Check out the full paper.

IMG_2827